PHAT
Phathom Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.50
+4.97%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 239.7M | 175.1M | 55.3M | 682.0K | — |
| Cost of Revenue | 40.9M | 22.6M | 8.0M | 167.0K | 620.0K |
| Gross Profit | 198.7M | 152.5M | 47.3M | 515.0K | (620.0K) |
| Operating Expenses | |||||
| R&D Expense | 30.1M | 32.8M | 34.1M | 49.9M | 71.4M |
| SG&A Expense | 209.3M | 279.7M | 290.7M | 117.9M | 100.4M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 239.4M | 312.5M | 324.7M | 167.8M | 171.8M |
| Cost and Expenses | 280.3M | 335.1M | 332.7M | 168.0M | 172.4M |
| Operating Income (EBIT) | (40.6M) | (160.0M) | (277.5M) | (167.3M) | (172.4M) |
| Non-Operating | |||||
| Interest Income | 5.9M | 7.0M | 15.2M | 7.9M | 2.1M |
| Interest Expense | 63.4M | 68.1M | 72.0M | 42.0M | 27.3M |
| Net Interest Income | (57.6M) | (61.1M) | (56.9M) | (34.1M) | (25.2M) |
| Other Non-Op Income/Expense | (58.4M) | (61.3M) | (56.9M) | (34.3M) | (25.3M) |
| Non-Operating Income (excl Interest) | (5.0M) | (6.9M) | (15.2M) | (7.7M) | (2.0M) |
| EBT (Pre-Tax Income) | (99.1M) | (221.2M) | (334.3M) | (201.6M) | (197.7M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (99.1M) | (221.2M) | (334.3M) | (201.6M) | (197.7M) |
| Earnings from Cont. Ops | (99.1M) | (221.2M) | (334.3M) | (201.6M) | (197.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (99.1M) | (221.2M) | (334.3M) | (201.6M) | (197.7M) |
| Per Share | |||||
| Basic EPS | ($1.28) | ($3.03) | ($5.29) | ($3.93) | ($5.70) |
| Diluted EPS | ($1.28) | ($3.03) | ($5.29) | ($3.93) | ($5.70) |
| Revenue Per Share | $2.86 | $2.40 | $0.87 | $0.01 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 83.7M | 72.9M | 63.2M | 51.3M | 39.1M |
| Diluted Shares Outstanding | 83.7M | 72.9M | 63.2M | 51.3M | 39.1M |
| Profitability Metrics | |||||
| EBITDA | (35.1M) | (152.5M) | (261.5M) | (159.0M) | (169.8M) |
| D&A | 508.0K | 633.0K | 795.0K | 575.0K | 620.0K |
| EBIT | (35.6M) | (153.1M) | (262.3M) | (159.6M) | (170.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026